SCHEMBL3665697

SCHEMBL3665697

COCCN1CCC(CC(OC(=O)N2CCN(c3ccc(C)cc3)CC2)C2CCN(CCOC)CC2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.47
ALDH1A1 P00352 2/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 2/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HTR7 P34969 1/20 0.40
DRD2 P14416 2/20 0.39
DRD3 P35462 1/20 0.39
GSK3B P49841 1/20 0.39
GFER P55789 1/20 0.39
CHRM4 P08173 1/20 0.38
HSD11B1 P28845 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
DRD4 P21917 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3672133 0.91 GPR119 (0.50) GPR119ALDH1A1GAAMAPTDRD2
SCHEMBL313990 0.82 MAPT (0.48) GPR119ALDH1A1POLBLMNAGAA
SCHEMBL4348614 0.78 GAA (0.45) GPR119ALDH1A1POLBLMNAGAA
SCHEMBL2977996 0.77 GPR119 (0.40) GPR119ALDH1A1LMNAGAAMAPT
SCHEMBL315197 0.73 CHRM4 (0.48) GPR119LMNAGAAMAPTKDM4E
SCHEMBL314082 0.73 L3MBTL1 (0.54) GPR119ALDH1A1LMNAGAAMAPT
SCHEMBL314754 0.73 CHRM4 (0.57) GPR119ALDH1A1LMNAGAAMAPT
SCHEMBL314976 0.72 CHRM4 (0.52) GPR119LMNAHTR7CHRM4SMN1; SMN2
SCHEMBL8350747 0.72 MAPT (0.58) ALDH1A1POLBMAPTHTR7DRD2
Hydrochloric Acid SCHEMBL314653 0.72 CHRM4 (0.47) GPR119ALDH1A1LMNAGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2234992-A2 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-10-06 EP disclosed
US-20090281087-A1 Compounds II BIOVITRUM AB (SE) 2009-11-12 US disclosed
WO-2009071668-A2 PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS BIOVITRUM AB (PUBL) (SE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281087-A1 Compounds II GPR119, FABP4, LIPC GPR119 1/4885ALDH1A1 2717/4885POLB 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.